Press Releases Archives | Page 19 of 119

Ncardia launches Ncyte® Heart in a Box

February 6, 2025 By Cade Hildreth, Founder & President Leave a Comment

LEIDEN, THE NETHERLANDS, February 6, 2025 – Ncardia, a leading human induced pluripotent stem cell (hiPSC) technology company, today announced the launch of Ncyte^® Heart in a Box, a breakthrough 3D cardiac microtissue model designed to drive innovation in cardiovascular research and drug discovery.

The Ncyte^® Heart in a Box system is derived from hiPSC and integrates three essential cardiac cell types: ventricular cardiomyocytes, endothelial cells, and cardiac fibroblasts. Together, these high-purity components form a physiologically relevant microtissue that replicates the complexity and functionality of the human heart. [Read more…]

I Peace establishes and offers low immunoreaction risk GMP iPS Cells

February 5, 2025 By BioInformant Team Leave a Comment

Three lines of GMP iPS Cells derived from type O female blood are now offered as off-the-shelf product

February 5, 2025, Palo Alto, CA – Leading GMP cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has established low immunoreaction risk GMP iPSCs derived from type O female blood and started offering as an off-the-shelf product. [Read more…]

VectorBuilder Powers FDA IND Approval of World’s First Umbilical Cord Blood-Derived Allogeneic CAR-T Product

February 5, 2025 By Cade Hildreth, Founder & President Leave a Comment

CHICAGO, IL, January 11, 2025 — VectorBuilder’s partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy, UC101, received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) on January 11, 2025. VectorBuilder has provided highly customized end-to-end CDMO solutions to support this clinical pipeline. [Read more…]

Ginkgo Bioworks Partners with Universal Cells, an Astellas Company, to Advance Next-Generation iPSC-Derived Cell Therapies for Solid Tumors

February 5, 2025 By Cade Hildreth, Founder & President Leave a Comment

Collaboration leverages Ginkgo’s cell engineering and screening platform to enhance the potency and persistence of Universal Cells’ iPSC-derived immune cell therapeutics

BOSTON, Jan. 13, 2025 – Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a research collaboration with Universal Cells, an Astellas company, to optimize next-generation induced pluripotent stem cell (iPSC)-derived cancer cell therapies. This collaboration underscores Ginkgo’s capacity to deploy high-throughput biological approaches to tackle the complex challenge set associated with development of therapies targeting solid tumors. [Read more…]

Ncardia launches Ncyte® Microglia

February 4, 2025 By BioInformant Team Leave a Comment

LEIDEN, THE NETHERLANDS, February 4, 2025 — Ncardia, a global leader in human induced pluripotent stem cell (hiPSC) technology, today announced the launch of Ncyte^® Microglia, a groundbreaking tool to advance research in neurodegenerative diseases and central nervous system (CNS) disorders.

Ncyte^® Microglia are hiPSC-derived models that closely mimic primary human microglia, exhibiting key functional characteristics such as phagocytosis, cytokine signaling response, and the expression of microglial markers including IBA1, TREM2, and TMEM119. These features make Ncyte^® Microglia highly suitable for studying microglial behavior in disease-relevant contexts, assessing immune responses, and enabling high-throughput drug screening applications. [Read more…]